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A
 
BSTRACT
 
Allergy to common agents, such as plant pollens, dust
mites and foods, is termed atopy. Atopy is the principal
cause of the chronic inflammatory diseases of eczema
(the skin), hayfever (the nose) and asthma (the lungs)
in children and young adults. Atopy affects millions of
individuals in Japan and other developed countries
and is a major source of chronic ill health in childhood
and of major health expenditure. Current treatments
only control symptoms and there is an urgent need for
a more fundamental understanding of the origins of
atopy in order to plan more effective treatment and
prevention. This may become a useful model for other
common multifactorial disease.
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I
 
NTRODUCTION
 
Shirakawa 
 
et al
 
.
 
1–4
 
 have conducted a collaborative
research program examining the origins of atopy over
the past 20 years and have provided evidence that
human genetic variation, single nucleotide polymorphisms
(SNP) and exposure to environmental factors in early
childhood are the key factors in this context. Their
identical twin studies
 
3
 
 indicated the importance of envi-
ronmental factors, as well as genetic factors, which
allow us to start an intervention study for the prevention
of allergic disorders.
 
S
 
INGLE
 
 
 
NUCLEOTIDE
 
 
 
POLYMORPHISMS
 
 
 
WITHIN
 
 
 
INTERLEUKIN
 
-4/
 
INTERLEUKIN
 
-13 
 
SIGNALING
 
 
 
OF
 
 
 
IMMUNITY
 
A revolutionary development in molecular genetic
research techniques has enabled us to examine the
human genome for the occurrence of genetic variants
that are relevant to the immune system and to the
development of allergy. We have been able to demon-
strate that genetic variants, influencing a number of
functions within the immune system, contribute to the
atopic disorder. In particular, we have emphasized the
importance of SNP within interleukin (IL)-4/IL-13 coding
genes (Table 1).
 
1
 
 These findings are of immediate
importance for the planning of new drug therapies in
atopy and asthma. However, this candidate approach,
although relevant, does not allow us to identify novel
genes. Therefore, we started, at SNP Research Center in
Riken, a case-control study screening the whole genome
for SNP that may be of interest for allergic disorders
using the linkage disequilibrium analysis. After 2 years
extensive work, our team has finally identified a final 37
candidate SNP for asthma (Table 2). However, allergy is
a multifactorial disease and the mechanisms by which
identified genetic variants interact each other have
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hardly been discussed. Using two major multivariate
analysis tools, namely logistic regression (LR) and
artificial neural network (ANN), our collaborators
investigated whether multiple candidate SNP can define
genetic predisposition to asthma. In addition, new tech-
niques have been introduced in collaboration with
several national centres on the basis of transcriptome,
proteome and other biological approaches to clarify
functional validation of candidate SNP.
 
L
 
IFESTYLE
 
 
 
FACTORS
 
 
 
AND
 
 I
 
G
 
E
 
It is widely acknowledged that the immune system is
affected by environmental and lifestyle factors. In a
large-scale industrial population, we performed a survey
with which we were able to demonstrate that several
comprehensive lifestyle factors, but not a single individ-
ual factor such as smoking, drinking or mental stress,
played a significant role in controlling the key allergic
molecule IgE (Table 3).
 
2
 
 IgE levels are also dependent
on a combination of multiple genetic variants, especially
among the IL-4 receptor and its signaling. Because there
is no model available to explain the interaction between
genetic and environmental factors, our model for IgE
may provide a new tool for analysing the interaction
between genetic and environmental factors.
 
A
 
SSOCIATION
 
 
 
OF
 
 
 
LIFESTYLE
 
 
 
WITH
 
 
 
A
 
 
 
HIGH
 
 
 
RISK
 
 
 
OF
 
 
 
HYPERIMMUNITY
 
 
 
AND
 
 
 
IMMUNOSUPPRESSION
 
 
 
MEDIATED
 
 
 
BY
 
 I
 
G
 
E
 
To test the hypothesis that the increase in allergic
prevalence is related not only to environmental aller-
gens, but also to comprehensive lifestyle, we adminis-
tered a questionnaire to 733 workers at a hard metal
plant that included 17 physical and mental health
practices.
 
3
 
 We have shown that eight practices are
associated with increases or decreases of total and
specific IgE levels, serving to keep them within the
normal range (5–400 IU/mL), after controlling for age,
sex and environmental factors. A significant (
 
P
 
 < 0.05)
trend for IgE to increase with a higher Health Practice
Index in Allergic Reaction (HPIA)
 
6
 
 category was found
within age astrata, whereas an age-related decline
(total) or increase (specific) in IgE level was found after
controlling for HPIA (Fig. 1).
 
3
 
Further confirmation of the definite effect of lifestyle on
allergic reactions comes from higher heritability among
younger pairs of identical twins of total IgE levels and
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Table 2
 
Final 37 candidate single nucleotide polymorphisms
for asthma
JSNP Phenotype
 
P
 
IMS-JSTNo 0.0020
IMS-JSTNo Childhood BA 0.0013
Childhood BA with higher IgE 0.00069
Severe childhood BA 0.00059
Childhood BA with mite IgE+ 0.00092
Childhood BA onset < 3 years 0.0035
Childhood BA treated with BDP 0.00081
IMS-JSTNo Childhood BA 0.0014
Childhood BA with higher IgE 0.00057
Severe childhood BA 0.0010
Childhood BA with AD 0.0017
Childhood BA with mite IgE+ 0.00074
Childhood BA onset < 3 years 0.0024
Childhood BA treated with BDP 0.0014
IMS-JSTNo Childhood BA 0.0015
Childhood BA with higher IgE 0.0022
Severe childhood BA 0.00071
Childhood BA with AD 0.0048
Childhood BA with mite IgE+ 0.0034
Childhood BA treated with BDP 0.00086
IMS-JSTNo Childhood BA with higher IgE 0.0074
IMS-JSTNo Adult BA 0.00014
Childhood BA with mite IgE+ 0.0077
Adult BA with higher IgE 0.000052
Severe adult BA 0.00062
IMS-JSTNo Childhood BA with higher IgE 0.0024
IMS-JSTNo Childhood BA 0.0065
Childhood BA with mite IgE+ 0.0085
Childhood BA onset < 3 years 0.00023
IMS-JSTNo Childhood BA 0.0077
Childhood BA with mite IgE+ 0.0058
Childhood BA onset < 3 years 0.00035
IMS-JSTNo Childhood BA onset < 3 years 0.00054
IMS-JSTNo Childhood BA with AD 0.0018
Childhood BA onset < 3 years 0.0057
IMS-JSTNo Childhood BA 0.0083
Childhood BA onset < 3 years 0.0018
IMS-JSTNo Childhood BA with AD 0.0024
Adult BA with nasal polyp 0.0065
IMS-JSTNo Childhood non-atopic BA 0.0020
IMS-JSTNo Childhood BA treated with BDP 0.0024
IMS-JSTNo Childhood BA 0.0040
Childhood BA with mite IgE+ 0.0012
Adult BA with history of child BA 0.0035
IMS-JSTNo Childhood BA 0.0051
Childhood BA with mite IgE+ 0.0015
Adult BA with history of child BA 0.0039
IMS-JSTNo Childhood BA 0.0083
Childhood BA with AD 0.0065
Childhood BA with mite IgE+ 0.0064
Childhood BA treated with BDP 0.00095
IMS-JSTNo Severe adult BA 0.0026
 
Table 2
 
Continued
 
JSNP Phenotype
 
P
 
IMS-JSTNo Severe childhood BA 0.0018
Childhood BA treated with BDP 0.0010
IMS-JSTNo Childhood BA 0.0018
Childhood BA with higher IgE 0.0092
Severe childhood BA 0.0034
Childhood BA with AD 0.0058
Childhood BA with mite IgE+ 0.0070
Childhood BA onset < 3 years 0.0048
Childhood BA treated with BDP 0.0034
IMS-JSTNo Childhood BA 0.0072
Childhood BA with higher IgE 0.0033
Childhood BA with AD 0.0022
Childhood BA onset < 3 years 0.00103
IMS-JSTNo Childhood BA with higher IgE 0.00061
IMS-JSTNo Childhood non-atopic BA 0.0050
IMS-JSTNo Adult BA 0.0036
Severe adult BA 0.0026
Adult BA with AIA 0.0099
IMS-JSTNo Childhood BA 0.0070
Adult BA 0.00070
Childhood BA treated with BDP 0.0097
Adult BA with higher IgE 0.0070
Severe adult BA 0.0029
IMS-JSTNo Adult BA 0.0082
IMS-JSTNo Childhood BA 0.0057
Adult BA 0.00069
Childhood BA with higher IgE 0.0039
Severe childhood BA 0.0089
Childhood BA treated with BDP 0.0085
Adult BA with higher IgE 0.0060
Severe adult BA 0.0040
IMS-JSTNo Adult BA 0.0030
Severe adult BA 0.0073
IMS-JSTNo Adult BA with higher IgE 0.0024
IMS-JSTNo Childhood BA 0.0061
Adult BA 0.0021
Childhood BA with higher IgE 0.010
Severe childhood BA 0.0084
Childhood BA treated with BDP 0.0079
Severe adult BA 0.0077
IMS-JSTNo Adult BA 0.0090
IMS-JSTNo Childhood BA with higher IgE 0.0021
IMS-JSTNo Severe adult BA 0.0065
IMS-JSTNo Adult BA 0.00074
Childhood BA treated with BDP 0.0084
Severe adult BA 0.0041
IMS-JSTNo Childhood BA with higher IgE 0.0045
IMS-JSTNo Adult BA with AIA 0.0063
 
JSNP, a database of Japanese single nucleotide polymorphisms;
BA, bronchial asthma; BDP, beclamethasane diproprionate; AD, atopic
dermatitis; AIA, aspirin-induced asthma.
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allergic disorders than among older pairs of identical
twins. A marked synergism was found between undesir-
able lifestyle factors such as bipolar high-risk factors for
the development of allergic diseases and immuno-
suppression characterized by low natural killer (NK) cell
activity, through which levels of the soluble low-affinity
IgE receptor are kept low.
 
3
 
 Therefore, an effort to practice
‘desirable’ lifestyles may be of benefit in reducing the risk
of immunoallergic disorders.
To examine the cumulative effect of lifestyle on
allergic disorders, we investigated allergy discordance in
monozygotic twin (MZT) pairs, as shown in Table 4.
 
3
 
 The
twin pairs were divided according to their allergic con-
cordance into the following three groups: (i) both positive
for allergy histories; (ii) only one positive; and (iii) neither
positive. In the MZT pairs, there was an apparent gradi-
ent between HPIA score, IgE levels and allergic symptoms
(Table 4).
 
3
 
 Pairs with both twins having positive allergy
 
Table 3
 
Risk of elevated cord blood IgE and maternal IgE related to mother’s age, frequency of birth, gender of baby, maternal
lifestyles, diet and environment factors
 
2
 
Risk factor Relative risk
Cord blood IgE 
(> 1.0 IU/mL)
Cord blood IgE 
(> 3.0 IU/mL)
Cord blood IgE 
(> 3.0 IU/mL) 
+ high-risk mother
 
a
 
Maternal IgE 
(> 400 IU/mL)
Frequency of birth
 
≤ 
 
1 2.4 (1.5–4.6)
 
b
 
3.3 (1.4–5.2)
 
b
 
2.5 (1.2–4.9)
 
b
 
1.6 (1.1–2.3)
 
c
 
Age of mother > 35 years 2.9 (1.8–5.0)
 
b
 
2.8 (1.3–5.0)
 
b
 
1.9 (1.2–3.3)
 
c
 
Gender of baby Boy 2.4 (1.2–4.8)
 
b
 
3.0 (1.5–5.0)
 
b
 
3.8 (2.0–5.8)
 
b
 
ND
Positive allergic history for Mother 2.8 (1.4–4.9)
 
b
 
ND 1.8 (1.0–2.2)
 
b
 
2.9 (1.7–4.8)
 
c
 
Father 1.3 (1.0–2.0)
 
c
 
Grandpa 1.3 (1.0–1.9)
 
b
 
Siblings 1.4 (1.0–2.4) 2.5 (1.5–4.1)
 
b
 
2.5 (1.6–4.0)
 
c
 
1.3 (1.4–2.0)
 
b
 
Maternal IgE > 400 IU/mL 2.8 (1.2–4.8)
 
b
 
ND 1.6 (1.0–2.2)
 
c
 
ND
Diet
Milk Every day 1.0 (0.3–2.0) 1.1 (0.5–2.2) 1.0 (0.4–2.0)
> 3.5  L/day 1.2 (0.3–2.5) 1.2 (0.3–2.5) 1.1 (0.3–2.2)
Eggs Every day 1.1 (0.3–2.2) 1.1 (0.5–2.3) 1.0 (0.8–1.9)
> 3 every day 1.0 (0.3–2.0) 1.1 (0.5–1.0) 0.9 (0.4–2.0)
Milk + eggs Every day 1.1 (0.4–2.3) 1.3 (1.0–2.0)
 
b
 
0.9 (0.3–1.9)
Tofu Every day 1.6 (1.0–2.2)
 
c
 
Soya beans Every day 2.8 (1.3–5.0)
 
b
 
2.8 (1.2–4.6)
 
b
 
3.8 (2.2–5.4)
 
b
 
Radishes Every day 0.2 (0.1–0.5)
 
b
 
Orange/pear Every day 0.3 (0.2–0.6)
 
b
 
0.3 (0.2–0.6)b
Peanuts ≥ 3/week 1.8 (1.1–2.4)b 1.8 (1.2–2.3)c
Lifestyle
Regularity Irregular 2.4 (1.2–4.4)b 2.8 (1.2–5.4)b 2.6 (1.1–4.6)b
Physical exercise < 1/week 2.5 (1.2–4.9)b 3.0 (1.3–5.5)b
Smoking habits Present/past 1.3 (1.0–1.8)c
Sleeping pattern ≤ 6 h 1.4 (1.0–2.0)c 2.5 (1.0–4.4)c
Coffee, tea ≥ 5 cups/day 0.7 (0.5–0.9)c
Life satisfaction Good 1.2 (1.0–1.4)c
HPIA Low 2.1 (1.1–4.4)c 2.4 (1.1–4.3)b 1.8 (0.4–2.6)c 2.1 (1.1–3.5)c
Environmental
House type Modern 1.9 (1.0–2.5)c 3.3 (1.3–5.0)b 2.9 (1.3–4.8)b
Facing large road Yes 1.2 (1.0–1.6)b
Carpets in home Yes 3.3 (1.5–5.0)b 1.2 (1.0–2.1)c 1.6 (1.0–2.2)c
Animals in home Yes 1.8 (1.0–2.4)c 1.8 (1.2–2.3)c
Multiple logistic analysis. Only factors with significant relative risk, except for exposure to eggs and milk, are listed.
Relative risk, odds ratio between high- and low-risk categories.
aWith high IgE (> 400 IU/mL) and/or positive allergic history.
bP < 0.01 on the basis of Chi-squared test; cP < 0.05.
HPIA, Health Practice Index in Allergic Reaction.6
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histories had a significantly (P < 0.05) higer mean HPIA
score (5.88 ± 0.88) than pairs with both having negative
allergy histories (4.60 ± 0.78). Among the pairs with one
twin positive, the person with a positive history of allergy
showed a significantly (P < 0.05) higher mean HPIA
score (5.67 ± 0.88) than the person without a positive
history (4.53 ± 0.85). These findings suggest that
discordance of lifestyle between pairs may cause dis-
cordance of total IgE levels, which is responsible for
discordance of allergic symptoms.7
HYGIENE HYPOTHESIS
Allergy is a disorder of the immune system, but the prime
function of the immune system is to protect the body
from harmful infectious agents. Consequently, the ques-
tion arises whether patterns of exposure to infectious
agents can influence the risk of allergy. It is clear that the
recent rapid rise in atopic disease has been seen in
‘developed’ environments, where exposure to infectious
agents in lungs and the intestine has fallen swiftly due to
Fig. 1 Cummulative impacts
of eight health practices in the
Health Practice Index in Allergic
Reaction (HPIA)6 on log (total
IgE levels) and cobalt-specific
IgE in male subjects with expo-
sure to hard metal dust. The
three categories are low (0–4),
medium (5,6) and high (7,8)
HPIA scores. After controlling for
age, the increases in total and
specific IgE levels were signifi-
cant (P < 0.05) between the
high and low HPIA categories.
In addition, there were signifi-
cant (P < 0.05) trends for IgE
to decrease (total) or increase
(specific) with age, except for
members of the low HPIA
category.3
Table 4 Association of allergic symptoms and Health Practice Index in Allergic Reaction (HPIA)6 score in monozygotic twins*
Reference Allergy No. pairs Age (years) Geometric 
mean IgE 
(IU/mL)
Intrapair 
correlation 
coefficient for IgE
Mean HPIA
Shirakawa et al.3 (all males) Both 13 64.6 ± 6.3 138.5a 5.88 ± 0.88a
Either
+ 26 62.3 ± 3.6 122.5a,b
– 26 62.3 ± 3.6 48.9 4.53 ± 0.85
Neither 22 61.6 ± 3.6 44.5 4.60 ± 0.78
Total 61 (33.3%) 62.8 ± 4.5 66.5 0.26
Hopp et al.12 Both 22
Either 9 6–31 42.1
Neither 30
Total 61 (71.0%) 0.82
Svartengren et al.13 Either (asthma)
+ 9 30–49 60.5 –0.015
– 9 30–49 27.2 –0.015
Edfors–Lubs7 2434 (24.4%) 35–75
*Note that discordance of allergic prevalence and/or total IgE levels is associated with age difference in populations studied.
aP < 0.05 compared with neither twin having symptoms; bP < 0.05 compared with one of the twins without symptoms.
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improved hygiene (Fig. 2).4,8,9 This is called the ‘hygiene
hypothesis’.
We have shown, in a large population of children from
Wakayama, that exposure to the tuberculosis microrgan-
isms in early life very strongly predicts less allergy and
asthma in later childhood (Table 5).5 We proposed that
such infections in early life program the immune system in
a way that is antagonistic to the development of allergic
disorders. Results of different investigations are given in
Table 6. Our suggestion has been confirmed by other
investigators, showing that tuberculosis organisms can
prevent experimental allergy in mice. In addition, it is well
known from recent epidemiological surveys10,11 that early
development of mucosal flora seems to be important in
preventing the future development of atopy. However, it
remains unknown how gut bacilli may interact with genes
predisposing to allergy. Thus, it is necessary to develop a
model to analyze the relationships between genetics and
environmental factors and to develop a ‘model’ to clarify
the effects of environmental factors. Our work may lead
to the development of vaccines that could be tested for
preventing allergy and asthma.
FUTURE PERSPECTIVE: GENERAL POPULATION 
SURVEY AT OGUNI TOWN
To verify our preventive strategy for allergic disorders, we
did our best to organize a general population survey at
Oguni Town, Kumamoto Prefecture, where our group
investigates all inhabitants to collect information on
genetic, environmental and lifestyle factors. We are now
making a new model to integrate these factors and to
predict the development of allergic disorders. The loca-
tion of Oguni Town is shown in Fig. 3. On the basis of
this model, we will develop a new preventive program
there.
Fig. 2 Trends in the number of
cases per 100 000 individuals
of Mycobacterium tuberculosis
() and of percentage preva-
lence of Ascaris lumbricoides
() infections and of atopic dis-
orders (, rhinitus; , eczema;
, asthma) in the past 50 years
in Japan. TB, tuberculosis.4 (Data
taken from Ministry of Health
and Welfare8 and Itoh.9)
Fig. 3 Location of Oguni Town, Aso Gun, Kumamoto
Prefecture.
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Throughout this study, we provided a new comprehen-
sive model to make profound understanding of patho-
genesis of allergic disorders by integrating ongoing
genetic analysis with environmental and lifestyle factors
and developed a preventive program, which may be
available for other common diseases.
Table 5 History of infectious diseases, atopic symptoms, IgE levels and cytokine profiles in subjects grouped by tuberculin
reactivity5
Measurement Group 1
(n = 290)
Group 2 
(n = 289)
Group 3 
(n = 213)
Group 4 
(n = 75)
Total§ 
(n = 867)
Tuberculin response
At 6 years – – + +
At 12 years – + + –
Positive antiviral immunity (%)
Measles (history + vaccine) 83.4 87.2 84.5 81.3 84.3
Chicken pox (history + vaccine) 86.9 82.3 82.2 82.7 83.9
Mumps (history + vaccine) 62.8 60.9 60.1 57.3 61.0
No. with IgE to Ascaris 2 2 2 1 7
Symptoms (%)
Atopy (past + present) 46.8 33.9‡‡ 25.8‡‡ 38.7 36.6
Atopy (present) 32.1 7.9‡‡‡ 9.8‡‡‡ 30.7 18.5
Asthma (past + present) 13.4 4.1‡‡ 3.7‡‡ 6.8 7.4
Rhinitis (past + present) 16.2 4.8‡‡ 8.6‡ 14.6 10.4
Eczema (past + present) 22.7 12.8‡‡ 12.2‡‡ 16.0 16.2
Geometric mean IgE (IU/mL) 208 149** 98*** 178 154
Positive ASE (%) 55.8 43.9‡‡ 41.8‡‡ 53.3 48.2
Atopic (high IgE or positive ASE %) 65.5 54.0‡‡ 49.2‡‡ 61.3 57.3
Median cytokine level (pg/mL)
IL-4 1.88 0.96† 0.92† 1.66 1.22 (10.2–UD)
IL-13 18.3 10.2††† 7.8††† 19.1 14.2 (45.6–UD)
IL-10 5.9 3.1†† 2.9†† 5.9 3.9 (10.2–UD)
IL-12 UD UD UD UD UD
IFN-γ 7.8 11.0†† 13.2†† 6.4 10.5 (23.2–UD)
Positive family history within three generations (%) 54.1 49.8 49.8 48.0 51.0
Mean BMI 21.1 22.0 21.9 21.2 21.6
**P < 0.01; ***P < 0.001 (Student’s t-test); †P < 0.05, ††P < 0.01, †††P < 0.001 (median test); ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 (χ2)
all compared with group 1.
§Where possible, maximum and minimum values are given in parentheses.
ASE, allergen-specific IgE; UD, undetectable; IL, interleukin; IFN, interferon; BMI, body mass index.
Table 6 Results of studies following the study of Shirakawa et al.5
Reference Country Study population Age (years) Wheezing/asthma Allergic disease
Number BCG
von Hertzen et al.14 Finland 2324 1162 ¶Adults Direct (men)/Inverse 
(women)*
Inverse†
von Mutius et al.15 23 countries 235 477 13–14 Inverse‡ Inverse‡
Shirtcliffe et al.16 38 countries 6–7 Inverse‡
Shirtcliffe et al.16 55 countries 13–14 Inverse‡
¶With tuberculosis (TB): *persistant asthma more frequent in men with TB, less frequent in women with TB at <16 years of age.
†Only in women;  ‡ecological analysis.
BCG, Bacillus Calmette–Guérin.
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